IP Library Granted Patent US 9,550,001
Granted Patent B2
US 9,550,001 · App. 14/128,347 · Granted Jan 24, 2017

Compositions, methods of synthesis and use of carbohydrate targeted agents

Inventors: Izabela Tworowska (Houston, TX); Jennifer Sims-Mourtada (Bellaire, TX); Ebrahim S. Delpassand (Houston, TX)
Assignee: RadioMedix Inc.
A61K51/0472A61K51/0491A61K51/0497C07H13/04C07H15/26C07H17/04C07H17/07C07H23/00A61K51/0482
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,550,001
App. No.
14/128,347
Granted
Jan 24, 2017
Kind
B2
Abstract

The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R 1 ′, R 2 ′ are each independently —OH or —O-alkyl; R 1 is a hydrogen, a linker, or a ligand; R 3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.

Claims (17)

1. A composition comprising a DO2S derivative conjugated to a monosaccharide ligand directly or through a linker and optionally chelated to a metal, wherein the DO2S derivative has the following structure:

wherein R 1 ′, and R 2 ′ are each independently —OH; R 1 , and R 3 comprise a ligand, optionally attached to the DO2S derivative via a linker; n is 1; the linker is an amino acid, a peptide, an amino alcohol, a polyethylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; and the ligand is a GLUT1 targeting moiety, wherein the GLUT-1 targeting moiety is 2-deoxyglucose, a 1′2′-diaminosugar, genistein, and/or scutellarin.

2. The composition of claim 1 , wherein the linker comprises —(CH2) m —X, wherein X is a hydroxyl, an amino, or a carboxyl group, and m is an integer from 1 to 10, and wherein the linker may be optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group.

3. The composition of claim 1 , wherein the DO2S derivative further comprises a radiometal.

4. The composition of claim 3 , wherein the radiometal is 68 Ga or 177 Lu.

5. A method for synthesizing a composition comprising a DO2S derivative conjugated to a monosaccharide ligand directly or through a linker and optionally chelated to a metal, wherein the DO2S derivative has the following structure:

wherein R 1 ′, and R 2 ′ are each independently —OH; R 1 , and R 3 comprise a ligand, optionally attached to the DO2S derivative via a linker; n is 1; the linker is an amino acid, a peptide, an amino alcohol, a polyethylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; and the ligand is a GLUT1 targeting moiety comprising a 2-deoxyglucose, a 1′2′-diaminosugar, genistein, and/or scutellarin, the method comprising the following steps:

providing the ligand bound to a branch linker at a proximal end of the branch linker, a distal end of the branch linker having two different reactive group ends;

attaching a first free reactive group end of the branch linker to a solid support;

deprotecting a second reactive group end of the branch linker;

conjugating the deprotected second reactive group end of the branch linker to a chelator to form a chelator-linker ligand conjugate DO2S derivative, immobilized on the solid support;

deprotecting functional carboxyl groups on the chelator;

radiolabeling the DO2S derivative immobilized on the solid support with an isotope; and

releasing the radiolabeled DO2S derivative from the solid support by cleavage of the branch linker from the solid support.

6. The composition of claim 1 , wherein the DO2S derivative further comprises a paramagnetic substance, the paramagnetic substance selected from the group consisting of Gd, Mn, Cu, and Fe.

7. The composition of claim 3 , wherein the radiometal is selected from the group consisting of a α-emitter, a β-emitter, a γ-emitter, and a β/γ-emitter.

8. The composition of claim 3 , wherein the radiometal is selected from the group consisting of 45 Ti, 59 Fe, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 89 Sr, 90 Y, 86 Y, 94m Tc, 99m Tc, 111 In, 149 Pm, 153 Gd, 153 Sm, 166 Ho, 186 Re, 188 Re, 211 At, 212 Bi, and 225 Ac.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 4, 2022
From: RADIOMEDIX INC
To: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 058609/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2014
From: TWOROWSKA, IZABELA; SIMS-MOURTADA, JENNIFER; DELPASSAND, EBRAHIM S.
To: RADIOMEDIX INC.
Reel/Frame 032620/0633 →
Continuity (2)
Provisional Application 61498950 · Jun 20, 2011
Related Publication 20140228551A1 · Aug 14, 2014